Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors

By Schlaeppi J-M.  

Cancer and Metastasis Reviews, Vol. 18, Iss. 4, 1999-12 ,pp. : 473-481

Springer Publishing Company

Access to resources Recommend Favorite

Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

By Sartore-Bianchi Andrea  

Targeted Oncology, Vol. 5, Iss. 1, 2010-03 ,pp. : 19-28

Springer Publishing Company

Access to resources Recommend Favorite

Anti-idiotypic antibody abagovomab in advanced ovarian cancer

By Bauerschlag Dirk O   Schem Christian   Baumann Klaus   Harter Philip   Hilpert Felix   Wagner Uwe   Bois Andreas du   Pfisterer Jakobus  

Future Oncology, Vol. 4, Iss. 6, 2008-12 ,pp. : 769-773

Future Medicine

Access to resources Recommend Favorite

Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 5, Iss. 2, 2010-06 ,pp. : 142-151

Bentham Science Publishers

Access to resources Recommend Favorite

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

By Witte L.  

Cancer and Metastasis Reviews, Vol. 17, Iss. 2, 1998-06 ,pp. : 155-161

Springer Publishing Company

Access to resources Recommend Favorite